Autor: |
Fadlalmola HA; Nursing college, Department of Community health nursing, Taibah University, Saudi Arabia., Elhusein AM; College of applied medical science, nursing department, University of Bisha, Bisha, Saudi Arabia.; University of Khartoum, Faculty of nursing, Khartoum, Sudan., Albadrani MS; College of medicine, Taibah University, Saudi Arabia., Masada HK; Applied medical college, Nursing Department, Hafr Albatin University, Saudi Arabia., Abdalla AM; Applied medical college, Nursing Department Shaqra University, Saudi Arabia., Elhussain MY; Applied medical college, Nursing Department, Hafr Albatin University, Saudi Arabia.; Alzaiem Alazhari University, Medical Technical colleague, Khartoum, Sudan., El-Amin EI; Ehab Ibrahim El-Amin, Department of Epidemiology, faculty of Public Health and Tropical Medicine., Azeem FM; Applied medical college, Nursing Department, Hafr Albatin University, Saudi Arabia. |
Jazyk: |
angličtina |
Zdroj: |
African journal of reproductive health [Afr J Reprod Health] 2023 Jan; Vol. 27 (1), pp. 95-106. |
DOI: |
10.29063/ajrh2023/v27i1.9 |
Abstrakt: |
Cesarean sections are the most common operations in the United States and one of the most common worldwide. Using the lowest possible dose of anesthetic that provides painless delivery with the lowest adverse events is a major concern. We investigated the efficacy and safety of combined ropivacaine and sufentanil by pooling data from relevant studies. We searched PubMed, Web of sciences, Scopus, and Cochrane Library until the end of December 2021 and included all records with data about combined ropivacaine and sufentanil. We used Review Manager to pool data as a mean difference for continuous outcomes or risk ratio for dichotomous outcomes with a 95% confidence interval. Methodological quality was appraised using version one of the Cochrane risks of bias tool. Seven Randomized clinical trials with a total sample size of 730 women were included; the mean age of enrolled parturients ranged from 28 to 35 years. We found that combined sufentanil and ropivacaine were significantly associated with decreased risk of being aware and nervous during CS (presented by Sedation level 1) (RR: 0.05, 95%CI [0.01,0.33], P=0.002), decreased risk of shivering (RR=0.29, 95%CI [0.19,0.44], P<0.00001), nausea (RR=0.62, 95%CI [0.41, 0.92], P=0.02), and vomiting (RR=0.27, 95% CI [0.12, 0.61], P=0.002). However, combined sufentanil and ropivacaine slightly were associated with late-onset of sensory blockade (MD=0.41, 95%CI [0.13, 0.68], P=0.004) and less motor blockade of leg flexion at hip joint presented by Bromage Scale 0 (RR=7.15 95%CI [2.71, 18.86], P<0.0001). Combined ropivacaine and sufentanil were associated with a reduction in visceral pain and lower risks of hypotension, shivering, nausea, and vomiting, compared to isolated ropivacaine, with no difference regarding the incidence of bradycardia. Although Combined ropivacaine and sufentanil were associated with a higher risk of pruritus, the incidence of pruritus was reportedly proportionate with the used dose of sufentanil. However, combined ropivacaine and sufentanil may slightly delay the onset of the sensory blockade to pinprick at T10 with less motor blockade but with a smaller probability for women to be aware and nervous during CS. |
Databáze: |
MEDLINE |
Externí odkaz: |
|